C3 and acute promyelocytic leukemia: While clinical trials with the anti-C5 eculizumab did not show any significant improvement in patients with MN, currently ongoing clinical trials with APL-2 (pegcetacoplan) (NCT03453619), which specifically binds to C3 and C3b preventing C3a formation, have the potential to show a significant improvement in the outcomes of affected individuals.